Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Cardiogenic shock pathophysiology

Introduction

Overview

Overview

The pathophysiology of cardiogenic shock is complex and not fully understood. Ischemia to the myocardium causes derangement to both systolic and diastolic left ventricular function, resulting in a profound depression of myocardial contractility. This, in turn, leads to a potentially catastrophic and vicious spiral of reduced cardiac output and low blood pressure, perpetuating further coronary ischemia and impairment of contractility. Several physiologic compensatory processes ensue. These include:The activation of the sympathetic system leading to peripheral vasoconstriction which may improve coronary perfusion at the cost of increased afterload, and Tachycardia which increases myocardial oxygen demand and subsequently worsens myocardial ischemia.These compensatory mechanisms are subsequently counteracted by pathologic vasodilation that occurs from the release of potent systemic inflammatory markers such as interleukin-1, tumor necrosis factor a, and interleukin-6. Additionally, higher levels of nitric oxide and peroxynitrite are released, which also contribute to pathologic vasodilation and are known to be cardiotoxic. Unless interrupted by adequate treatment measures, this self-perpetuating cycle leads to global hypoperfusion and the inability to effectively meet the metabolic demands of the tissues, progressing to multiorgan failure and eventually death.

Pathophysiology

Pathophysiology

The downward “Spiral” of Cardiogenic shock

The downward “Spiral” of Cardiogenic shock

Right Ventricle Myocardial Infarction

Right Ventricle Myocardial Infarction

Ventricular Septal and Free Wall Rupture

Ventricular Septal and Free Wall Rupture

Inflammation and Hemodynamics

Inflammation and Hemodynamics

Iatrogenic Cardiogenic Shock

Histopathological Findings Of myocardial infarction and plaque rupture

Histopathological Findings Of myocardial infarction and plaque rupture

http://www.peir.net Images courtesy of Professor Peter Anderson DVM PhD and published with permission Β© PEIR, University of Alabama at Birmingham, Department of Pathology]

References

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Reynolds, H. R.; Hochman, J. S. (2008). “Cardiogenic Shock: Current Concepts and Improving Outcomes”. Circulation. 117 (5): 686–697. doi:10.1161/CIRCULATIONAHA.106.613596. ISSNΒ 0009-7322.
  2. ↑ 2.0 2.1 Hollenberg SM, Kavinsky CJ, Parrillo JE (1999). “Cardiogenic shock”. Ann Intern Med. 131 (1): 47–59. PMIDΒ 10391815.
  3. ↑ Hasdai, David. (2002). Cardiogenic shockΒ : diagnosis and treatmen. Totowa, N.J.: Humana Press. ISBNΒ 1-58829-025-5.
  4. ↑ Hasdai, David. (2002). Cardiogenic shockΒ : diagnosis and treatmen. Totowa, N.J.: Humana Press. ISBNΒ 1-58829-025-5.
  5. ↑ Hasdai, David. (2002). Cardiogenic shockΒ : diagnosis and treatmen. Totowa, N.J.: Humana Press. ISBNΒ 1-58829-025-5.
  6. ↑ Hasdai, David. (2002). Cardiogenic shockΒ : diagnosis and treatmen. Totowa, N.J.: Humana Press. ISBNΒ 1-58829-025-5.
  7. ↑ Bolli R, MarbΓ‘n E (1999). “Molecular and cellular mechanisms of myocardial stunning”. Physiol Rev. 79 (2): 609–34. PMIDΒ 10221990.
  8. ↑ Hasdai, David. (2002). Cardiogenic shockΒ : diagnosis and treatmen. Totowa, N.J.: Humana Press. ISBNΒ 1-58829-025-5.
  9. ↑ Bolli R (1998). “Basic and clinical aspects of myocardial stunning”. Prog Cardiovasc Dis. 40 (6): 477–516. PMIDΒ 9647607.
  10. ↑ Marban E (1991). “Myocardial stunning and hibernation. The physiology behind the colloquialisms”. Circulation. 83 (2): 681–8. PMIDΒ 1991384.
  11. ↑ Isner JM, Roberts WC (1978). “Right ventricular infarction complicating left ventricular infarction secondary to coronary heart disease. Frequency, location, associated findings and significance from analysis of 236 necropsy patients with acute or healed myocardial infarction”. Am J Cardiol. 42 (6): 885–94. PMIDΒ 153103.
  12. ↑ 12.0 12.1 12.2 12.3 12.4 Ng, R.; Yeghiazarians, Y. (2011). “Post Myocardial Infarction Cardiogenic Shock: A Review of Current Therapies”. Journal of Intensive Care Medicine. 28 (3): 151–165. doi:10.1177/0885066611411407. ISSNΒ 0885-0666.
  13. ↑ Reeder GS (1995). “Identification and treatment of complications of myocardial infarction”. Mayo Clin Proc. 70 (9): 880–4. doi:10.1016/S0025-6196(11)63946-3. PMIDΒ 7643642.
  14. ↑ Lavie CJ, Gersh BJ (1990). “Mechanical and electrical complications of acute myocardial infarction”. Mayo Clin Proc. 65 (5): 709–30. PMIDΒ 2190052.
  15. ↑ Jacobs AK, Leopold JA, Bates E, Mendes LA, Sleeper LA, White H; et al. (2003). “Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry”. J Am Coll Cardiol. 41 (8): 1273–9. PMIDΒ 12706920.
  16. ↑ Brookes, C.; Ravn, H.; White, P.; Moeldrup, U.; Oldershaw, P.; Redington, A. (1999). “Acute Right Ventricular Dilatation in Response to Ischemia Significantly Impairs Left Ventricular Systolic Performance”. Circulation. 100 (7): 761–767. doi:10.1161/01.CIR.100.7.761. ISSNΒ 0009-7322.
  17. ↑ 17.0 17.1 Figueras J, Alcalde O, BarrabΓ©s JA, Serra V, Alguersuari J, Cortadellas J; et al. (2008). “Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period”. Circulation. 118 (25): 2783–9. doi:10.1161/CIRCULATIONAHA.108.776690. PMIDΒ 19064683.
  18. ↑ Becker RC, Gore JM, Lambrew C, Weaver WD, Rubison RM, French WJ; et al. (1996). “A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction”. J Am Coll Cardiol. 27 (6): 1321–6. PMIDΒ 8626938.
  19. ↑ Becker RC, Hochman JS, Cannon CP, Spencer FA, Ball SP, Rizzo MJ; et al. (1999). “Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study”. J Am Coll Cardiol. 33 (2): 479–87. PMIDΒ 9973029.
  20. ↑ Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA; et al. (2000). “Cardiogenic shock complicating acute myocardial infarction–etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?”. J Am Coll Cardiol. 36 (3 Suppl A): 1063–70. PMIDΒ 10985706.
  21. ↑ Thompson CR, Buller CE, Sleeper LA, Antonelli TA, Webb JG, Jaber WA; et al. (2000). “Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK?”. J Am Coll Cardiol. 36 (3 Suppl A): 1104–9. PMIDΒ 10985712.
  22. ↑ Crenshaw BS, Granger CB, Birnbaum Y, Pieper KS, Morris DC, Kleiman NS; et al. (2000). “Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators”. Circulation. 101 (1): 27–32. PMIDΒ 10618300.
  23. ↑ Radford MJ, Johnson RA, Daggett WM, Fallon JT, Buckley MJ, Gold HK; et al. (1981). “Ventricular septal rupture: a review of clinical and physiologic features and an analysis of survival”. Circulation. 64 (3): 545–53. PMIDΒ 7020978.
  24. ↑ 24.0 24.1 Skehan JD, Carey C, Norrell MS, de Belder M, Balcon R, Mills PG (1989). “Patterns of coronary artery disease in post-infarction ventricular septal rupture”. Br Heart J. 62 (4): 268–72. PMCΒ 1277362. PMIDΒ 2803872.
  25. ↑ SWITHINBANK JM (1959). “Perforation of the interventricular septum in myocardial infarction”. Br Heart J. 21: 562–6. PMCΒ 1017615. PMIDΒ 13836145.
  26. ↑ Cohn, Lawrence (2012). Cardiac surgery in the adult. New York: McGraw-Hill Medical. ISBNΒ 978-0-07-163310-9.
  27. ↑ Oliva PB, Hammill SC, Edwards WD (1993). “Cardiac rupture, a clinically predictable complication of acute myocardial infarction: report of 70 cases with clinicopathologic correlations”. J Am Coll Cardiol. 22 (3): 720–6. PMIDΒ 8354804.
  28. ↑ 28.0 28.1 28.2 Slater J, Brown RJ, Antonelli TA, Menon V, Boland J, Col J; et al. (2000). “Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?”. J Am Coll Cardiol. 36 (3 Suppl A): 1117–22. PMIDΒ 10985714.
  29. ↑ Figueras J, Cortadellas J, Soler-Soler J (2000). “Left ventricular free wall rupture: clinical presentation and management”. Heart. 83 (5): 499–504. PMCΒ 1760810. PMIDΒ 10768896.
  30. ↑ Cohn, Lawrence (2012). Cardiac surgery in the adult. New York: McGraw-Hill Medical. ISBNΒ 007163312X.
  31. ↑ Cohn, Lawrence (2012). Cardiac surgery in the adult. New York: McGraw-Hill Medical. ISBNΒ 007163312X.
  32. ↑ Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD; et al. (1999). “Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock”. N Engl J Med. 341 (9): 625–34. doi:10.1056/NEJM199908263410901. PMIDΒ 10460813.
  33. ↑ Picard MH, Davidoff R, Sleeper LA, Mendes LA, Thompson CR, Dzavik V; et al. (2003). “Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock”. Circulation. 107 (2): 279–84. PMIDΒ 12538428.
  34. ↑ Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA; et al. (2005). “Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock”. Arch Intern Med. 165 (14): 1643–50. doi:10.1001/archinte.165.14.1643. PMIDΒ 16043684.
  35. ↑ Hochman, J. S. (2003). “Cardiogenic Shock Complicating Acute Myocardial Infarction: Expanding the Paradigm”. Circulation. 107 (24): 2998–3002. doi:10.1161/01.CIR.0000075927.67673.F2. ISSNΒ 0009-7322.
  36. ↑ Brunkhorst FM, Clark AL, Forycki ZF, Anker SD (1999). “Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation”. Int J Cardiol. 72 (1): 3–10. PMIDΒ 10636626.
  37. ↑ Hasdai, David. (2002). Cardiogenic shockΒ : diagnosis and treatmen. Totowa, N.J.: Humana Press. ISBNΒ 1-58829-025-5.
  38. ↑ Neumann, F.-J.; Ott, I.; Gawaz, M.; Richardt, G.; Holzapfel, H.; Jochum, M.; Schomig, A. (1995). “Cardiac Release of Cytokines and Inflammatory Responses in Acute Myocardial Infarction”. Circulation. 92 (4): 748–755. doi:10.1161/01.CIR.92.4.748. ISSNΒ 0009-7322.
  39. ↑ Shah, A (2000). “Inducible nitric oxide synthase and cardiovascular disease”. Cardiovascular Research. 45 (1): 148–155. doi:10.1016/S0008-6363(99)00316-8. ISSNΒ 0008-6363.
  40. ↑ Feng Q, Lu X, Jones DL, Shen J, Arnold JM (2001). “Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice”. Circulation. 104 (6): 700–4. PMIDΒ 11489778.
  41. ↑ Cotter G, Kaluski E, Blatt A, Milovanov O, Moshkovitz Y, Zaidenstein R; et al. (2000). “L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock”. Circulation. 101 (12): 1358–61. PMIDΒ 10736276.
  42. ↑ Kaluski E, Hendler A, Blatt A, Uriel N (2006). “Nitric oxide synthase inhibitors in post-myocardial infarction cardiogenic shock–an update”. Clin Cardiol. 29 (11): 482–8. PMIDΒ 17133844.
  43. ↑ Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R (2000). “Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure”. Circ Res. 87 (3): 241–7. PMIDΒ 10926876.
  44. ↑ Geppert A, Dorninger A, Delle-Karth G, Zorn G, Heinz G, Huber K (2006). “Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction”. Crit Care Med. 34 (8): 2035–42. doi:10.1097/01.CCM.0000228919.33620.D9. PMIDΒ 16775569.
  45. ↑ Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M (2006). “Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure”. Crit Care Med. 34 (8): 2140–4. doi:10.1097/01.CCM.0000229144.97624.90. PMIDΒ 16763507.
  46. ↑ Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG; et al. (2003). “Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial”. Circulation. 108 (10): 1184–90. doi:10.1161/01.CIR.0000087447.12918.85. PMIDΒ 12925454.
  47. ↑ APEX AMI Investigators. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D; et al. (2007). “Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial”. JAMA. 297 (1): 43–51. doi:10.1001/jama.297.1.43. PMIDΒ 17200474.
  48. ↑ De Backer D, Creteur J, Dubois MJ, Sakr Y, Vincent JL (2004). “Microvascular alterations in patients with acute severe heart failure and cardiogenic shock”. Am Heart J. 147 (1): 91–9. PMIDΒ 14691425.
  49. ↑ De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL (2002). “Microvascular blood flow is altered in patients with sepsis”. Am J Respir Crit Care Med. 166 (1): 98–104. PMIDΒ 12091178.
  50. ↑ Trzeciak S, Dellinger RP, Parrillo JE, Guglielmi M, Bajaj J, Abate NL; et al. (2007). “Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival”. Ann Emerg Med. 49 (1): 88–98, 98.e1–2. doi:10.1016/j.annemergmed.2006.08.021. PMIDΒ 17095120.
  51. ↑ Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS; et al. (2005). “Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock”. JAMA. 294 (4): 448–54. doi:10.1001/jama.294.4.448. PMIDΒ 16046651.
  52. ↑ Jeger, R. V. (2006). “Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry”. European Heart Journal. 27 (6): 664–670. doi:10.1093/eurheartj/ehi729. ISSNΒ 0195-668X.
  53. ↑ Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM; et al. (2005). “Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative”. Am Heart J. 149 (6): 1043–9. doi:10.1016/j.ahj.2005.02.010. PMIDΒ 15976786.
  54. ↑ “ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group”. Lancet. 345 (8951): 669–85. 1995. PMIDΒ 7661937.
  55. ↑ “Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group”. Circulation. 97 (22): 2202–12. 1998. PMIDΒ 9631869.
  56. ↑ Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX; et al. (2005). “Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial”. Lancet. 366 (9497): 1622–32. doi:10.1016/S0140-6736(05)67661-1. PMIDΒ 16271643. Review in: ACP J Club. 2006 May-Jun;144(3):58-9 Review in: Evid Based Med. 2006 Jun;11(3):82-3


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammad Salih, MD. JoΓ£o AndrΓ© Alves Silva, M.D. [2] Syed Musadiq Ali M.B.B.S.[3]